NasdaqCM:CLDXBiotechs
Did Celldex’s (CLDX) US$300 Million Equity Raise to Fund Barzolvolimab Just Shift Its Investment Narrative?
In early April 2026, Celldex Therapeutics completed a follow-on public equity offering of 10,345,000 common shares at US$29.00 each, raising about US$300.01 million to support barzolvolimab launch preparation, pipeline development and general corporate needs.
This financing closely followed detailed Phase 2 data showing barzolvolimab’s potential to meaningfully improve quality of life in difficult-to-treat chronic urticaria, underscoring Celldex’s focus on translating clinical momentum into...